Bioventus Inc. (BVS) research
Bioventus Inc.- Sector
- Health Care
- Last price
- $13.65
- As of
Bioventus Inc. (BVS): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-05.
As of . Source: SEC EDGAR filings for BVS. Method and limitations.
Share the BVS intelligence card
See BVS live in the terminal
Track BVS's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live BVS terminal, freeActive signals for BVS
- highCONSENSUS_BUY
4 tracked funds increased BVS this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased BVS this 2026Q2, institutional consensus
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in BVS
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +1124% to BVS (2026Q2)
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +50% to BVS (2026Q2)
FREE, NO ACCOUNT
Every signal on BVS, as it fires
You are seeing 5 of 28 signals recorded on BVS since 2026-05-31.
The five above landed across 2 days. The other 23 were recorded on 3 other days. 20 of the 28 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in BVS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 09075A108 · 2026Q2 | $6.9M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 09075A108 · 2026Q2 | $2.2M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 09075A108 · 2026Q2 | $1.9M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 09075A108 · 2026Q2 | $1.6M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 09075A108 · 2026Q2 | $447K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BVS
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
BVS against its peers
BVS's operating margin of 9.5% ranks in the 87th percentile of 25 Health Care sub-industry peers, fiscal periods ending between 2025-10-03 and 2026-05-31.
| Metric | BVS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 568M USD | 764M USD | 48 | 25 |
| Gross margin | 68.3% | 54.6% | 70 | 14 |
| Operating margin | 9.5% | -2.0% | 87 | 25 |
| Net margin | 4.0% | -4.9% | 87 | 25 |
| Return on equity | 12.3% | -5.3% | 94 | 24 |
| P / E | 41.4x | 47.6x | 31 | 7 |
Peers (25): TALK, HSTM, VREX, AHCO, STAA, CSTL, PRCT, EHAB, IRMD, TDOC, GDRX, TNDM, ANGO, USPH, CERT, FLGT, OMDA, AMN, CNMD, PNTG, CERS, CTEV, OMCL, ATEC, SGHT. Fiscal periods ending between 2025-10-03 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (BVS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more BVS signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to BVSand get the insider, 13F, options, and confluence read in one view.